Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 9—September 2008

Research

Pediatric Parapneumonic Empyema, Spain

Ignacio ObandoComments to Author , Carmen Muñoz-Almagro, Luis A. Arroyo, David Tarrago, David Sanchez-Tatay, David Moreno-Perez, Sahar S. Dhillon, Cristina Esteva, Susanna Hernandez-Bou, Juan J. Garcia-Garcia, William P. Hausdorff, and Angela B. Brueggemann
Author affiliations: Virgen del Rocio Children’s Hospital, Seville, Spain (I. Obando, L.A. Arroyo, D. Sanchez-Tatay); Sant Joan de Deu Hospital, Barcelona, Spain (C. Muñoz-Almagro, C. Esteva, S. Hernandez-Bou, J.J. Garcia-Garcia); Spanish Reference Laboratory for Pneumococci, Madrid, Spain (D. Tarrago); Carlos de Haya Children’s Hospital, Malaga, Spain (D. Moreno-Perez); University of Oxford, Oxford, UK (S.S. Dhillon, A.B. Brueggemann);; GlaxoSmithKline Biologicals, Rixensart, Belgium (W.P. Hausdorff);

Main Article

Table 1

Demographic characteristics of 208 patients with PPE enrolled during the molecular analysis study period*

Characteristic Value
Age, mo, mean ± SD (range) 51.8 ± 31 (2–180)
Gender ratio, M/F 1.06
Underlying disease, %† 4
Oral antimicrobial drugs before admission, %‡ 29
Antimicrobial drug free before thoracocentesis, %§ 23
PCV7 >1 dose, % 31
Referral, % 38

*PPE, pediatric parapneumonic empyema; PCV7, 7-valent pneumococcal conjugate vaccine.
†Underlying disease included (no. patients): lymphoma (2), congenital heart disease (2), mild psychomotor retardation (2), varicella zoster infection (2) and genetic disease (1).
‡Median duration: 3 d, range 1–17 d.
§100/147 children who had not been treated with oral antimicrobial drug therapy before admission received intravenous antimicrobial drug treatment before thoracocentesis for a median of 2 d (range 1–10 d).

Main Article

TOP